60 results on '"Berno, Tamara"'
Search Results
2. Hospitalization-based epidemiology of systemic and cardiac amyloidosis in the Veneto Region, Italy
3. Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review
4. Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital
5. Chest pain in cardiac amyloidosis: occurrence, causes and prognostic significance
6. P-129 Real world evidence of prognostic impact of t(14;16) translocation in multiple myeloma: a report of the myeloma triveneto working group
7. P1111: WALDENSTRÖM MACROGLOBULINEMIA IN THE VERY ELDERLY (≥75-YEAR-OLD): DESCRIPTION OF CLINICAL FEATURES AND SURVIVAL OUTCOMES IN A CASE SERIES FROM AN ITALIAN ACADEMIC CENTER
8. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
9. Light-chain cardiac amyloidosis for the non-expert: pearls and pitfalls
10. Peripheral neuropathy as clinical onset of monoclonal IgM/k‐related amyloidosis
11. CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma
12. 193 Epidemiological trend of amyloidosis and its association with cardiovascular conditions: a single-center report
13. 325 Dealing with cardiac amyloidosis diagnosis: keep calm and use the magnifying glasses!
14. 188 Disarming the bomb in AL amyloidosis: a case report
15. Dealing with high-risk AL Amyloidosis patients: a single hematologic Center Experience.
16. Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
17. Cardiovascular Complications in Patients with AL Amyloidosis
18. Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients
19. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate
20. Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
21. Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis
22. Immune Profiling of Plasma Cell Dyscrasias Reveals a Therapy Related T-Cell Modulation in Multiple Myeloma Patients
23. Immunomodulatory drugs in plasma cell diseases: everything has its price
24. Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case–control study
25. Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians
26. Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study
27. Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients
28. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI
29. A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma
30. Effect of low‐dose bortezomib on bone formation in smouldering multiple myeloma
31. Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
32. STAT3 mutation impacts biological and clinical features of T-LGL leukemia
33. Diffusion Weighted Whole Body MRI for Evaluation of Early Response in Multiple Myeloma
34. Infections in Multiple Myeloma: An Understimate Risk Factor of Comorbidity
35. Hyperammonemic Encephalopathy as Initial Presentation of Multiple Myeloma
36. Lenalidomide long-term neurotoxicity
37. Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells
38. Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience
39. Identification of a STAT3-miRNA Axis in T-LGL Leukemia
40. Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation
41. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors
42. Effect Of Low Dose Bortezomib On Bone Formation In Smoldering Myeloma Patients
43. Histone deacetylase inhibitors
44. NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy
45. Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?
46. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study
47. Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies
48. Mechanisms of Thrombosis in Paraproteinemias: The Effects of Immunomodulatory Drugs
49. Low-risk identification in multiple myeloma using a new 14-gene model
50. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.